Abstract: Provided herein are compounds of formula (I): and pharmaceutically-acceptable salts thereof, where A, W, X, Y and Z are defined in the specification. The compounds of formula (I) and pharmaceutically-acceptable salts thereof are Janus kinase (JAK) inhibitors. Also provided herein are pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat, e.g., inflammatory and fibrotic diseases, including respiratory diseases.

Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Abstract: Disclosed are systems and methods for generating graphical displays of analyte data and/or health information. In some implementations, the graphical displays are generating based on a self-referential dataset that are modifiable based on identified portions of the data. The modified graphical displays can indicate features in the analyte data of a host.

Abstract: A system and method for balancing flows of renal replacement fluid is disclosed. The method uses pressure controls and pressure sensing devices to more precisely meter and balance the flow of fresh dialysate and spent dialysate. The balancing system may use one or two balancing devices, such as a balance tube, a tortuous path, or a balance chamber.

Abstract: The present disclosure generally relates to a multi-disk drive comprising a plurality of media surfaces and a plurality of heads, wherein a head of the plurality of heads is configured to be actuated over each surface of the plurality of media surfaces. The multi-disk drive further comprises control circuitry configured to write data to a first media surface of the plurality of media surfaces using a first head of the plurality of heads, and after all of an available memory of the first media surface has been filled, write data to a second media surface of the plurality of media surfaces using a second head of the plurality of heads. The control circuitry is further configured to permanently disable write access to one or more media surfaces of the plurality of media surfaces, while continuing to permit read access to the plurality of media surfaces.

Abstract: Provided herein are purification, production and manufacturing methods for recombinant viral vector particles such as recombinant adeno-associated viral (rAAV) vector particles substantially free of empty viral particles; a population of recombinant adeno-associated vims (rAAV) particles purified using the method described herein, and a pharmaceutical composition comprising the purified rAAV.

Abstract: The application is directed to methods and devices for estimating corrosion of a material. One of the methods includes obtaining data regarding corrosion. The data is obtained from various sources, such as but not limited to sensors and observational data. The data is then trained to provide for a more complete data set. The trained data is then used to estimate the expected amount of corrosion for a given situation.

Abstract: A melt-blown fabric for pouching smokeless tobacco or a smokeless tobacco substitute can include melt-blown polymer fibers. The fabric can have a basis weight of less than 30 gsm and a tensile strength of at least 4mJ in at least one predetermined direction. Method of making the fabric can include melt-blowing a polymeric material against a support surface and bonding the fibers or arranging them in a predetermined orientation. Pouched smokeless tobacco or tobacco substitute products including the fabrics provided herein can provide desirable flavor and tactile experience.

Abstract: A medical device comprising an enclosure defining a cavity for containing agent, a lumen for receiving a pressurized gas, and a barrier positioned between the cavity and the lumen, the barrier including at least one opening for storing agent, wherein rotation of the barrier relative to the lumen establishes fluid communication between the at least one opening and the lumen for delivering agent from the at least one opening to the lumen.

Abstract: Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.

Abstract: An aqueous treating medium may include water; an acid selected from the group consisting of: HCl, HBr, HNO3, H2SO4, H2SO3, H3PO4, H3PO2, HOAc, citric acid, tartaric acid, ascorbic acid, EDTA, methanesulfonic acid, toluenesulfonic acid, and combinations thereof, wherein a concentration of the acid in the aqueous treating medium is from 0.5 M to 1.5 M; a salt, wherein a concentration of the salt in the aqueous treating medium is from greater than 0 M to 2 M; a fluoride-containing compound selected from the group consisting of: HF, NaF, NH4HF2, and combinations thereof, wherein a concentration of the fluoride-containing compound in the aqueous treating medium is from 0.026 M to 0.26 M; and silica, wherein the aqueous treating medium is saturated with silica.

Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Abstract: Apparatus for continuous ink jet printing, comprising: an ink system comprising an ink storage tank (15) operable to supply ink to a print head associated with the apparatus; a single cartridge connection (9) for releasable engagement with a fluid cartridge (8), the cartridge connection (9) comprising: a fluid connector (10) for engaging an outlet of a fluid cartridge; and a conduit configured to allow fluid to flow along a fluid pathway from a cartridge engaged with the cartridge connection, via the fluid connector, to the ink storage tank. The apparatus has a first configuration in which a solvent cartridge is engaged with the cartridge connection and in which the apparatus is configured to receive solvent from the engaged solvent cartridge, and a second configuration in which an ink cartridge is engaged with the cartridge connection and in which the apparatus is configured to receive ink from the engaged ink cartridge.

Abstract: Methods and systems for determining whether a software application that is executable by an electronic device is compliant under the Health Insurance Portability and Accountability Act (HIPAA) are provided. A software application is accessed over a network. A programmed computer processor is used to determine whether said software application, upon execution, is at or above an (i) access control threshold, (ii) audit control threshold, (iii) data integrity threshold, (iv) authentication threshold, and (v) transmission security threshold, which thresholds are minimum thresholds for HIPAA compliance. Additionally, a determination that said software application is HIPAA compliant is made if said software application, upon execution, is at or above (i) said access control threshold, (ii) audit control threshold, (iii) data integrity threshold, (iv) authentication threshold, and (v) transmission security threshold. Further, a determination as to whether said software application is HIPAA compliant is output.

Abstract: The technology provides a system for controlling illumination of a luminous keyboard. A non-transitory storage medium stores a trained machine learning model for identifying a user sentiment. A processor receives at least one keyboard input entered by the user. The processor processes the keyboard input using the trained machine learning model to identify a sentiment or behavior of the user. The processor determines an illumination profile for the keyboard based on the identified user sentiment or behavior. The keyboard illuminates according to the illumination profile.

Abstract: An apparatus for enrobing a product portion can include at least one polymer spray head adapted to create at least one flow of polymeric fibers to produce at least one polymer enrobing zone and a conveyor system adapted to move at least one product portion from at least one position below at least one polymer enrobing zone and to at least one position above at least one polymer enrobing zone to drop each product portion through one or more polymer enrobing zones a plurality times at different orientations to enrobe each product portion with polymeric fibers.

Abstract: A document production system may construct a document from fragments based on a theme associated with the document. The theme may contain section(s), each section having an access control list (ACL) associated therewith. The ACL may specify role-based user group(s) and permission(s) for the role-based user group(s). The system may evaluate rules applicable to the document. At least one rule may pertain to the ACL(s). The evaluation may include, at least in part, utilizing user login information received over a network from a client device. In constructing the document, the system may assemble the document in accordance with the rules and utilizing the fragments and meta information that describes the document. The system may render the document thus assembled utilizing the ACL, generate a view of the document, and communicate the view of the document over the network to the client device for presentation on the client device.

Abstract: Disclosed communication flow modeling solution is significantly streamlined in a user friendly way to shield users from the technical complexities usually required. At design time, an orchestration flow modeling application receives user instruction to open or create a communication flow modeling project. Per configuration specific to an enterprise associated with the user, a custom drag-and-drop communication flow modeling environment with a canvas and modeling entities is provided. Responsive to the user dragging and dropping a set of modeling entities from the menu onto the communication flow modeling canvas and drawing connections between them, the orchestration flow modeling application logically connects the modeling entities to form a valid communication flow and stores it in a database. The communication flow undergoes an approval process. Once approved, it is activated for execution by an orchestration server.

Abstract: Pharmaceutical compositions include heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.

Abstract: Methods and systems for establishing a chain of relationships are disclosed. An identity verification platform receives a first request for registration comprising an identification of a first user, identification of an entity, and a relationship between the first user and the entity; verifies the identity of the first user and the relationship between the first user and the entity; and verifies that the entity is legitimate. Once a relationship between a first individual, invited by the first user, and the entity is confirmed, the platform creates a custom badge representing the relationship between the first individual and the entity for display on the entity's website. The platform receives an identification of a selection by an end user of the custom badge and, responsive to receiving the identification of the selection, renders, on a domain controlled by the identity verification platform, a verification that the relationship between the first individual and the entity is valid.